Ancora Biotech
Ancora Biotech is a clinical-stage biopharmaceutical company developing breakthrough biotherapeutics for B cell cancers, metabolic diseases, and chronic hepatitis B infection. Formed by former Teneobio executives and venture investors, it oversees three therapeutic programs across separate spinoffs — TeneoTwo (TNB-486, a T cell engager in Phase I for B-cell malignancies), TeneoFour (TNB-738, an anti-CD38 antibody for inflammatory and metabolic disorders), and TeneoTen (an anti-HBV T cell engager for hepatitis B). It is a drug-development company with no public developer API or platform surface.
Ancora Biotech is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Biopharmaceutical, Healthcare, and Life Sciences.
Kin Score
Resources
Company 1
The organization behind the API